Absci Raises $100 Million in Equity to Fund AI-Designed Programs for Hair Loss and Endometriosis
Absci Corporation has raised $100 million through an equity offering to advance its AI-designed programs targeting hair loss (androgenetic alopecia) and endometriosis. The company also reported positive interim Phase 1 results for ABS-201, showing favorable safety and pharmacokinetics.
Tickers: $ABSI
Topics: ai drug development biotech endometriosis research hair loss treatment